General Group Discussion — Problems in Study Design
Dr. Sami: My question is for Dr. Temple. I am a Canadian and not really involved with the F.D.A.; but if you were presented with a drug, let’s say a beta blocker, which had identical action to propranolol and identical side effects, identical efficacy in every respect, would that make a problem in approving this drug for clinical use or not?
KeywordsPlacebo Toxicity Ischemia Europe Expense
Unable to display preview. Download preview PDF.